All In Biotech

Drug Trial Radar · NCT07379125

Therapeutic RSK1 Targeting in Myeloid Malignancies

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 20, 2026

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Phoenix Molecular Designs; The Foundation for Barnes-Jewish Hospital; Swim Across America; Blood Cancer United
First posted
Jan 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study hypothesizes that PMD-026, an oral inhibitor of ribosomal protein S6 kinase A1 (RSK1), is safe and well tolerated in participants with myelofibrosis (MF) and myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPNs) and will improve spleen response, symptom response, and bone marrow histopathological response.

Conditions

  • Myeloid Malignancy

Interventions

  • PMD-026Drug

    PMD-026 is an oral drug which will be taken every 12 hours on an outpatient basis at the assigned dose every day of each 28-day cycle. Provided by Phoenix Molecular Designs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: From cycle 1 day 1 through 28 days after last dose (estimated to be 1 year and 28 days)
  2. Number of participants with dose limiting toxicities (DLTs) based on occurrence of serious treatment-emergent adverse events (Dose Escalation only)Time frame: During cycle 1 of treatment (each cycle is 28 days)
  3. Recommended phase II dose (RP2D) (Dose Escalation only)Time frame: Completion of cycle 1 (each cycle is 28 days) of all dose-escalation patients (estimated to be 1 year and 28 days)
  4. Changes in spleen size (Dose Expansion and RP2D Cohort in Dose Escalation)Time frame: Baseline and after 24 weeks of treatment (estimated to be 24 weeks)
  5. Changes in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 Total Symptom Score (Dose Expansion and PR2D Cohort in Dose Escalation)Time frame: Baseline and after 24 weeks of treatment (estimated to be 24 weeks)
  6. Bone marrow histopathologic response (Dose Expansion and RP2D Cohort in Dose Escalation)Time frame: Baseline and after 24 weeks of treatment (estimated to be 24 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.